Changes in use of disease-modifying antirheumatic drugs for rheumatoid arthritis in the United States during 1983-2009

Arthritis Care and Research

Volumn 65, Issue 9, 2013, Pages 1529-1533

  Kim, Seoyoung C ^a   Yelin, Ed ^b   Tonner, Chris ^b   Solomon, Daniel H ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; AZATHIOPRINE; CERTOLIZUMAB PEGOL; CYCLOPHOSPHAMIDE; CYCLOSPORIN D; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLD DERIVATIVE; GOLIMUMAB; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; PENICILLAMINE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; SALAZOSULFAPYRIDINE; STEROID;

ARTICLE; CLINICAL FEATURE; CLINICAL PRACTICE; DRUG UTILIZATION; HUMAN; LONG TERM CARE; RHEUMATOID ARTHRITIS; TREND STUDY; UNITED STATES;

AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COHORT STUDIES; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; UNITED STATES;

EID: 84883239965     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.21997     Document Type: Article

References (13)

1. Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012; 64: 625-39.
2. Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008; 59: 762-84.
3. Schmajuk G, Schneeweiss S, Katz JN, Weinblatt ME, Setoguchi S, Avorn J, et al. Treatment of older adult patients diagnosed with rheumatoid arthritis: improved but not optimal. Arthritis Rheum 2007; 57: 928-34.
4. Schmajuk G, Trivedi AN, Solomon DH, Yelin E, Trupin L, Chakravarty EF, et al. Receipt of disease-modifying antirheumatic drugs among patients with rheumatoid arthritis in Medicare managed care plans. JAMA 2011; 305: 480-6.
5. Solomon DH, Ayanian JZ, Yelin E, Shaykevich T, Brookhart MA, Katz JN,. Use of disease-modifying medications for rheumatoid arthritis by race and ethnicity in the National Ambulatory Medical Care Survey. Arthritis Care Res (Hoboken) 2012; 64: 184-9.
6. Yelin EH, Henke CJ, Kramer JS, Nevitt MC, Shearn M, Epstein WV,. A comparison of the treatment of rheumatoid arthritis in health maintenance organizations and fee-for-service practices. N Engl J Med 1985; 312: 962-7.
7. Yelin EH, Criswell LA, Feigenbaum PG,. Health care utilization and outcomes among persons with rheumatoid arthritis in fee-for-service and prepaid group practice settings. JAMA 1996; 276: 1048-53.
8. Katz PP, Morris A, Yelin EH,. Prevalence and predictors of disability in valued life activities among individuals with rheumatoid arthritis. Ann Rheum Dis 2006; 69: 1803-8.
9. Armitage P,. Tests for linear trends in proportions and frequencies. Biometrics 1955; 11: 375-86.
10. Lee SJ, Chang H, Yazici Y, Greenberg JD, Kremer JM, Kavanaugh A,. Utilization trends of tumor necrosis factor inhibitors among patients with rheumatoid arthritis in a United States observational cohort study. J Rheumatol 2009; 36: 1611-7.
11. Edwards CJ, Arden NK, Fisher D, Saperia JC, Reading I, van Staa TP, et al. The changing use of disease-modifying anti-rheumatic drugs in individuals with rheumatoid arthritis from the United Kingdom General Practice Research Database. Rheumatology (Oxford) 2005; 44: 1394-8.
12. Lacaille D, Anis AH, Guh DP, Esdaile JM,. Gaps in care for rheumatoid arthritis: a population study. Arthritis Rheum 2005; 53: 241-8.
13. Ziegler S, Huscher D, Karberg K, Krause A, Wassenberg S, Zink A,. Trends in treatment and outcomes of rheumatoid arthritis in Germany 1997-2007: results from the National Database of the German Collaborative Arthritis Centres. Ann Rheum Dis 2010; 69: 1803-8.